본문으로 건너뛰기
← 뒤로

Post-endoscopic retrograde cholangiopancreatography bowel evisceration in a liver transplant recipient previously treated with atezolizumab-bevacizumab: first report.

증례보고 1/5 보강
Revista espanola de enfermedades digestivas 📖 저널 OA 10.3% 2022: 0/2 OA 2024: 0/7 OA 2025: 1/30 OA 2026: 5/19 OA 2022~2026 2026 Vol.118(2) p. 109-110
Retraction 확인
출처

Santos-Pérez E, Gomercic C, Thobois M, Frin AC, Ouizeman D, Vanbiervliet G

📝 환자 설명용 한 줄

Hepatocellular carcinoma (HCC) treatment increasingly involves liver transplantation (LT), often after downstaging therapies.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Santos-Pérez E, Gomercic C, et al. (2026). Post-endoscopic retrograde cholangiopancreatography bowel evisceration in a liver transplant recipient previously treated with atezolizumab-bevacizumab: first report.. Revista espanola de enfermedades digestivas, 118(2), 109-110. https://doi.org/10.17235/reed.2025.11518/2025
MLA Santos-Pérez E, et al.. "Post-endoscopic retrograde cholangiopancreatography bowel evisceration in a liver transplant recipient previously treated with atezolizumab-bevacizumab: first report.." Revista espanola de enfermedades digestivas, vol. 118, no. 2, 2026, pp. 109-110.
PMID 41128087 ↗

Abstract

Hepatocellular carcinoma (HCC) treatment increasingly involves liver transplantation (LT), often after downstaging therapies. Atezolizumab, a PD-L1 inhibitor, combined with bevacizumab, an anti-VEGF agent, is widely used, showing high response rates pre-transplant. However, bevacizumab impairs angiogenesis and can significantly increase the risk of wound dehiscence, infection, and delayed healing after major surgery, including LT.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반